Previous Article | Next Article ![]()
Journal of Virology, August 2002, p. 7560-7570, Vol. 76, No. 15
0022-538X/02/$04.00+0 DOI: 10.1128/JVI.76.15.7560-7570.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Stephen H. Hughes,3 and Maxine L. Linial1,2*
Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109,1 Department of Microbiology, University of Washington, Seattle, Washington 98195,2 ABL-Basic Research Program, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 217023
Received 22 August 2001/ Accepted 23 April 2002
Foamy virus (FV) replication is resistant to most nucleoside analog reverse transcriptase (RT) inhibitors. In an attempt to create a 2',3'-dideoxy-3'-thiacytidine (3TC)-sensitive virus, the second residue in the highly conserved YXDD motif of simian foamy virus-chimpanzee (human isolate) [SFVcpz(hu)] RT was changed from Val (V) to Met (M). Unexpectedly, the resultant virus, SFVcpz(hu) RT-V313M, replicated poorly, and Met rapidly reverted to Val. Despite the presence of approximately 50% of wild-type RT activity in RT-V313M virions, full-length DNA products were not detected in transfected cells. Using purified recombinant enzymes, we found that the wild-type FV RT is significantly more processive than human immunodeficiency virus type 1 RT. However, the V313M mutant has about 40% of the wild-type level of FV RT activity and has a lower processivity than the wild-type FV enzyme. The V313M mutant RT is also relatively resistant to 3TC. These results suggest that the decrease in RT activity and processivity of FV RT-V313M prevents completion of reverse transcription and greatly diminishes viral replication.
Present address: University of Washington School of Medicine, Seattle, WA 98195.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|